scholarly journals Successful Ocreotide and Medium-Chain Triglyceride Therapy for Cylothorax in a Patient with Noonan Syndrome: Case Report

2010 ◽  
Vol 30 (4) ◽  
pp. 1402-1405
Author(s):  
Sumru BEDER ◽  
Zinet Gül ERSOY ◽  
Emine GÜLLÜ ◽  
G. Eda UTINE ◽  
Oya KAYACAN ◽  
...  
Keyword(s):  
Case Report ◽  
Noonan Syndrome ◽  
Medium Chain Triglyceride ◽  
Medium Chain

Refractory primary intestinal lymphangiectasia effectively managed with subcutaneous octreotide

2021 ◽  
Vol 14 (4) ◽  
pp. e238457
Author(s):  
Amir Halim ◽  
Philippa Youd ◽  
Jill Thorpe ◽  
Irfan Halim
Keyword(s):  
Case Report ◽  
Gastrointestinal Symptoms ◽  
Medium Chain Triglyceride ◽  
Well Being ◽  
Intestinal Lymphangiectasia ◽  
Curative Therapy ◽  
Medium Chain ◽  
History Of ◽  
Medium Chain Triglyceride Diet ◽  
Conventional Medium

This case report describes a young man with a history of lymphoedema and long-standing gastrointestinal symptoms since childhood. After undergoing extensive investigations, he was diagnosed with primary intestinal lymphangiectasia (IL). The patient’s condition was refractory to conventional medium-chain triglyceride diet but responded well to treatment with subcutaneous octreotide. We have shown octreotide to be effective in improving the pathological effects of primary IL, associated with improved clinical well-being and serology, but it is not a curative therapy.

scholarly journals Use of Sirolimus in a Premature Neonate With Kaposiform Hemangioedema

2021 ◽  
Vol 26 (2) ◽  
pp. 205-209
Author(s):  
Jason Koury ◽  
Miel Brown ◽  
Suzzette Sturtevant ◽  
Cody Wiley ◽  
Linda Felton
Keyword(s):  
Case Report ◽  
Treatment Option ◽  
Medium Chain Triglyceride ◽  
Lesion Size ◽  
Premature Neonate ◽  
High Morbidity ◽  
Kaposiform Hemangioendothelioma ◽  
Medium Chain ◽  
Trough Concentrations ◽  
D Dimer

Kaposiform hemangioendothelioma (KHE) is a rare, vascular malignancy that is often associated with coagulopathies and thrombocytopenia secondary to platelet trapping. Typically, a person diagnosed with KHE with Kasabach-Merritt phenomenon (KMP) presents with a reddish-purplish lesion, thrombocytopenia, and elevated D-dimer, which can lead to high morbidity and mortality. Sirolimus has been identified as a treatment option for KHE with or without KMP for reduction in lesion size and hematologic parameters. In this case report, a female born at 26.5 weeks was noted at birth to have a purpuric lesion on her right upper back and flank area. She was diagnosed with biopsy-confirmed KHE with KMP. She was started on sirolimus 0.01 mg (0.02 mg/kg; 0.14 mg/m2) once a day, and because of high trough concentrations treatment was held until concentrations decreased. Sirolimus was then microdiluted to a 0.01 mg/mL concentration in medium-chain triglyceride oil for administration. Prior to discharge from the hospital the commercially available product was dispensed for home use. After 6 months of treatment, she achieved a reduction in lesion size and improvement in hematologic parameters, and treatment was stopped at 9 months.

scholarly journals Congenital chylous as cites in a 3-month-old infant in Zaria: A case report

2021 ◽  
Vol 48 (2) ◽  
pp. 96-98
Author(s):  
S.M. Abdullahi ◽  
H.W. Idris ◽  
S.M. Mado ◽  
A.H. Sadiku ◽  
A. Alfa ◽  
...  
Keyword(s):  
Case Report ◽  
Lymphatic System ◽  
Medium Chain Triglyceride ◽  
Chylous Ascites ◽  
Individual Therapy ◽  
Medium Chain ◽  
Diagnosis And Therapy ◽  
Nutrition Medium ◽  
Per Oral ◽  
Abdominal Paracentesis

Congenital chylous ascites (CCA) is a rare disease that results from the maldevelopment of the intra-abdominal lymphatic system. Due to the rarity of congenital chylous ascites and the lack of standards in diagnosis and therapy, this disease constitutes a medical challenge and individual therapy seems to be extremely important. A 3-month-old girl diagnosed with congenital chylous ascites. She was managed initially with nil per oral, parenteral nutrition, medium chain triglyceride (MCT) containing oil and abdominal paracentesis, followed by octreotide. Medium chain triglyceride formula, the main stay of management was discontinued with gradual reintroduction of breast feeds. This case was selected due to the rarity of CCA and the lack of standards in the diagnosis and therapy.

Rare NRAS mutation causing Noonan syndrome type 6 in a Saudi patient: case report

2021 ◽  
pp. 413-415
Author(s):  
Sara Alomar ◽  
Anfal Alsultan ◽  
Halah AlMuhaidib ◽  
Sarah Aldhahri ◽  
Dalal Bubshait
Keyword(s):  
Case Report ◽  
Noonan Syndrome ◽  
Syndrome Type ◽  
Patient Case ◽  
Nras Mutation

scholarly journals Stabilisation of Lutein and Lutein Esters with Polyoxyethylene Sorbitan Monooleate, Medium-Chain Triglyceride Oil and Lecithin

Foods ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 500
Author(s):  
Zala Gombač ◽  
Ilja Gasan Osojnik Črnivec ◽  
Mihaela Skrt ◽  
Katja Istenič ◽  
Andreja Knez Knafelj ◽  
...  
Keyword(s):  
Aqueous Solutions ◽  
Medium Chain Triglyceride ◽  
Storage Conditions ◽  
Sorbitan Monooleate ◽  
Medium Chain ◽  
Poorly Soluble

Lutein is a challenging compound to incorporate into food, as it is poorly soluble and unstable in aqueous solutions. In this study, the aim was to prepare stable encapsulates of lutein and lutein esters using feasible and straightforward techniques. Fine suspensions based on polyoxyethylene sorbitan monooleate and medium-chain triglyceride oil micelle-like units with 3.45% lutein esters or 1.9% lutein equivalents provided high encapsulation efficiencies of 79% and 83%, respectively. Lutein encapsulated in fine suspensions showed superior stability, as 86% was retained within the formulation over 250 days at 25 °C in the dark. Under the same storage conditions, only 38% of lutein remained in corresponding formulations. Higher encapsulation efficiencies were achieved with lecithin emulsions, at up to 99.3% for formulations with lutein, and up to 91.4% with lutein esters. In lecithin emulsions that were stored for 250 days, 17% and 80% of lutein and lutein esters, respectively, were retained within the formulations.

P-155 Persistant thrombocytopenia in Noonan syndrome with juvenile myelomonocytic leukemia: A case report

2013 ◽  
Vol 37 ◽  
pp. S93-S94
Author(s):  
A. Eischen ◽  
C. Paillard ◽  
M. Besse ◽  
A. Spiegel ◽  
P. Lutz ◽  
...  
Keyword(s):  
Case Report ◽  
Noonan Syndrome ◽  
Juvenile Myelomonocytic Leukemia ◽  
Myelomonocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document